Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Impella
MedTech
J&J MedTech growth slows again as Abiomed weighs on results
J&J’s MedTech unit posted 3.6% operational growth in Q2, reaching $8.93 billion, as weaker Abiomed sales weighed on performance.
Ben Adams
Jul 15, 2026 9:57am
FDA issues early alert for Abiomed device over bleeding risk
Jun 23, 2026 8:09am
J&J’s Impella pumps miss the mark in 2 major PCI studies
Mar 30, 2026 3:20pm
J&J delivers 10-year Impella gains in severe heart attacks
Sep 2, 2025 1:30pm
FDA opens use of J&J's Impella heart pumps to pediatric patients
Dec 12, 2024 2:30pm
J&J's Abiomed pump reduces deaths after widowmaker heart attacks
Apr 8, 2024 12:12pm
